Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.
Alyssa A TooropLaura HogenboomKarien BloemMerve KocyigitNadine W M CommandeurAnne WijnantsBirgit I Lissenberg-WitteEva M M StrijbisBernard M J UitdehaagTheo RispensJoep KillesteinZoé Léonie Elise van KempenPublished in: Journal of neurology, neurosurgery, and psychiatry (2023)
Serum ocrelizumab concentration was strongly associated with B-cell count. Measurement of ocrelizumab drug concentrations and ADAs could play an important role to further personalise treatment and predict the start of B-cell repopulation.